Inventiva Pharma

Beleggen in aandelen beurzen Frankfurt DAX, Londen FTSE 100, Parijs CAC40, etc.
Plaats reactie
Gillepils
Forum actieveling
Forum actieveling
Berichten: 593
Lid geworden op: 25 Aug 2016 08:48
waarderingen: 143
Contact:

Re: Inventiva Pharma

Berichtdoor Gillepils » 23 Mei 2018 08:48

Blackbelt schreef:Eerste pakketjes is binnen aan 7,44, maar mijn order is niet volledig uitgevoerd.
Volumes zijn zeer laag voor dit aandeel...


Er is ook heel weinig 'free float' en daar is dan nog een deel van in handen van institutionals...


Brammeke
Forum actieveling
Forum actieveling
Berichten: 477
Lid geworden op: 19 Okt 2016 15:33
waarderingen: 144
Contact:

Re: Inventiva Pharma

Berichtdoor Brammeke » 30 Mei 2018 00:15

bijgekocht aan 7,60.
gemiddeld aan 7,57.

Brammeke
Forum actieveling
Forum actieveling
Berichten: 477
Lid geworden op: 19 Okt 2016 15:33
waarderingen: 144
Contact:

Re: Inventiva Pharma

Berichtdoor Brammeke » 12 Jun 2018 09:16

INVENTIVA to Present at the 2018 JMP Securities Life Sciences Conference


11 juni 2018 17:45

Inventiva to Present at the 2018 JMP Securities Life Sciences Conference
Daix (France), June 11, 2018 - Inventiva S.A. ("Inventiva" or the "Company"), a biopharmaceutical company developing innovative therapies in nonalcoholic steatohepatitis (NASH), systemic sclerosis (SSc) and mucopolysaccharidosis (MPS), today announced that Frédéric Cren, Chief Executive Officer and co-founder of Inventiva, will participate in the panel discussion "NASH: Making Sense of the Pipeline" at the upcoming 2018 JMP Securities Life Sciences Conference being held on June 20-21, 2018 at The St. Regis New York hotel, New York, USA. The event details are as follows:
Date: Thursday, June 21, 2018
Time: 08:00 am (Eastern Time)
Panel: "NASH: Making Sense of the Pipeline"
Location: Louis XVI room, The St. Regis New York hotel
About Inventiva: http://www.inventivapharma.com
Inventiva is a biopharmaceutical company specialized in the development of drugs interacting with nuclear receptors, transcription factors and epigenetic modulators. Inventiva's research engine opens up novel breakthrough therapies against fibrotic diseases, cancers and orphan diseases with substantial unmet medical needs.
Lanifibranor, its lead product, is an anti-fibrotic treatment acting on the three alpha, gamma and delta PPARs (peroxisome proliferator-activated receptors), which play key roles in controlling the fibrotic process. Its anti-fibrotic action targets two initial indications with substantial unmet medical need: NASH, a severe and increasingly prevalent liver disease already affecting over 30 million people in the United States, and systemic sclerosis, a disease with a very high mortality rate and for which there is no approved treatment to date.
Inventiva is also developing a second clinical program with odiparcil (IVA 336) for the treatment of patients with mucopolysaccaridosis type VI (or Maroteaux-Lamy syndrome), a rare and severe gene disease affecting children. Odiparcil has also the potential to address other MPS types, characterized by the accumulation of chondroitin or dermatan sulfate (MPS I or Hurler/Sheie syndrome, MPS II or Hunter syndrome, MPS IVa or Morqio syndrome and MPS VII or Sly syndrome). Inventiva is also developing a portfolio of early research projects in the field of oncology.
Inventiva benefits from partnerships with world-leading research entities such as the Institut Curie in the field of oncology. Two strategic partnerships have also been established with world-class major pharmaceutical companies AbbVie and Boehringer Ingelheim in the fields of autoimmune diseases (specifically in psoriasis) and fibrosis respectively. These partnerships provide milestone payments to Inventiva upon the achievement of pre-clinical, clinical, regulatory and commercial milestones, in addition to royalties on the products resulting from the partnerships.
Inventiva employs over 100 highly qualified employees and owns state-of-the-art R&D facilities near Dijon, acquired from the international pharmaceutical group Abbott. The Company owns, a proprietary chemical library of over 240,000 molecules as well as integrated biology, chemistry, ADME and pharmacology platforms.
Gillepils liked last!

Blackbelt
Forum actieveling
Forum actieveling
Berichten: 555
Lid geworden op: 04 Nov 2013 22:29
waarderingen: 179
Contact:

Re: Inventiva Pharma

Berichtdoor Blackbelt » 14 Jun 2018 22:20

Ingestapt aan 7,41 gemiddeld.

Brammeke
Forum actieveling
Forum actieveling
Berichten: 477
Lid geworden op: 19 Okt 2016 15:33
waarderingen: 144
Contact:

Re: Inventiva Pharma

Berichtdoor Brammeke » 21 Jun 2018 10:04

Press Release: INVENTIVA : FDA Approval of an Investigator Initiated IND Application to Conduct Phase II Study of Lanifibranor in Type 2 Diabetic Patients with Non-Alcoholic Fatty Liver Disease

Press Release: INVENTIVA : FDA Approval of an Investigator Initiated IND Application to Conduct Phase II Study of Lanifibranor in Type 2 Diabetic Patients with Non-Alcoholic Fatty Liver Disease
FDA Approval of an Investigator Initiated IND Application to Conduct Phase II Study of Lanifibranor in Type 2 Diabetic Patients with Non-Alcoholic Fatty Liver Disease -- Study to enroll first patient in the third quarter 2018 with topline results expected early 2020 -- FDA approval is a positive signal for SSc and NASH IND applications Daix (France) June 20, 2018 - Inventiva S.A. ("Inventiva" or the "Company"), a biopharmaceutical company developing innovative therapies in nonalcoholic steatohepatitis (NASH), systemic sclerosis (SSc) and mucopolysaccharidosis (MPS), today announced that the U.S. Food and Drug Administration (FDA) has accepted the investigator initiated Investigational New Drug (IND) application providing clearance to proceed with the Phase II study of lanifibranor in type 2 diabetic patients with nonalcoholic fatty liver disease (NAFLD). This FDA approval is also a positive signal for the planned Company IND applications in SSc and NASH. The trial to be conducted by Dr. Kenneth Cusi, Chief of the Division of Endocrinology, Diabetes & Metabolism in the Department of Medicine at the University of Florida, Gainesville, is expected to enroll 64 patients treated for a 24-week period with a single daily dose of lanifibranor (800 mg/day) or placebo and 10 subjects in a healthy, non-obese control group. The study´s overall objective is to measure the metabolic improvements induced by lanifibranor, and its effect on steatosis in type 2 diabetic patients with NAFLD. Additionally, this study will detect lanifibranor´s impact on fibrosis using the most recent imaging and biomarker technology. Its main endpoints are a decrease of liver steatosis assessed by state-of-the-art imaging, including H-MRS (Proton Magnetic Resonance Spectroscopy), a decrease of insulin resistance (glucose clamp, HBA1c), a decrease in de novo lipogenesis, and safety. The first patient is expected to be enrolled in the third quarter of 2018 and topline results are expected beginning of 2020. "With its unique pan-PPAR profile, lanifibranor has shown very good safety features, relevant efficacy data in NASH preclinical models as well as positive metabolic effects in a Phase IIa study in diabetic patients," Dr. Cusi said. "We anticipate the results of this study to translate well to diabetic patients with NAFLD or NASH and look forward to demonstrating that lanifibranor could become a very valuable drug for these patients." Jean-Louis Abitbol, MD, MSC, Chief Medical Officer of Inventiva, added: "We are delighted that the FDA has allowed Dr Cusi and his team to proceed with this exciting metabolic and imaging study and we very much look forward to the enrollement of US patients as these results will provide additional supporting data for our regulatory filings with US and European regulators."
Stofke liked last!

Stofke
Forum gebruiker
Forum gebruiker
Berichten: 208
Lid geworden op: 13 Okt 2017 16:18
waarderingen: 115
Contact:

Re: Inventiva Pharma

Berichtdoor Stofke » 21 Jun 2018 22:39

De Amerikaanse Food & Drug Administration (FDA) heeft de IND-aanvraag (Investigational New Drug Application) goedgekeurd die nodig is om te starten met een door onderzoekers geïnitieerde Lanifibranor fase II-studie bij patiënten met diabetes type 2 die lijden aan niet-alcoholische leververvetting. In april liet Inventiva weten dat het hoofd van de afdeling Endocrinologie, Diabetes en Metabolisme aan de universiteit van Florida Lanifibranor had geselecteerd voor een fase II-studie. Die studie zal 64 patiënten rekruteren die gedurende 24 weken behandeld worden met ofwel een placebo, ofwel een enkele dosis Lanifibranor één maal per dag. De eerste inschrijvingen worden verwacht in het derde kwartaal van 2018, met toplijnresultaten begin 2020.
Dat Lanifibranor wordt gekozen voor een door onderzoekers geïnitieerde studie toont volgens analist Lenny Van Steenhuyse de interesse van de medische gemeenschap aan en benadrukt het brede potentieel van de molecule. Bovendien valideert de IND-goedkeuring van de FDA het veiligheidsprofiel van Lanifibranor, wat in het verleden voor dit type molecule niet altijd het geval was. Het is ook een goed voorteken voor toekomstige IND-aanvragen die het bedrijf wil indienen voor niet-alcoholische leverontsteking (NASH) en systemische sclerose. De resultaten van deze lopende fase II-studies worden resp. in de tweede helft van 2019 en begin 2019 verwacht. Kortom, een duidelijk positieve ontwikkeling voor Inventiva, nu een door een Amerikaanse onderzoeker geïnitieerd onderzoek kan starten met het inschrijven van patiënten. Dit wordt de derde lopende fase II-studie met Lanifibranor, naast NASH en systemische sclerose.